by Portfolio Grader | March 13, 2013 9:00 am
The overall ratings of eight Biotechnology stocks are down on Portfolio Grader[1] this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Discovery Laboratories (NASDAQ:DSCO[2]) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, DSCO also gets F’s. For a full analysis of DSCO stock, visit Portfolio Grader[3].
The rating of Achillion (NASDAQ:ACHN[4]) declines this week from C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of March 13, 2013, 16.2% of outstanding Achillion shares were held short. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock[5].
Genomic Health (NASDAQ:GHDX[6]) earns a D this week, moving down from last week’s grade of C. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock has a trailing PE Ratio of 115.00. For more information, get Portfolio Grader’s complete analysis of GHDX stock[7].
Acorda Therapeutics (NASDAQ:ACOR[8]) is having a tough week. The company’s rating falls from C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For a full analysis of ACOR stock, visit Portfolio Grader[9].
Amarin’s (NASDAQ:AMRN[10]) rating weakens this week, dropping to a D versus last week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock gets F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of March 13, 2013, 16% of outstanding Amarin shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock[11].
Exelixis (NASDAQ:EXEL[12]) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of March 13, 2013, 20.3% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock[13].
Trius Therapeutics (NASDAQ:TSRX[14]) experiences a ratings drop this week, going from last week’s C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader[15].
This week, BioSpecifics Technologies’ (NASDAQ:BSTC[16]) rating worsens to a D from the company’s C rating a week ago. BioSpecifics Technologies is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. The stock gets F’s in Earnings Surprise and Margin Growth. The trailing PE Ratio for the stock is 50.40. For more information, get Portfolio Grader’s complete analysis of BSTC stock[17].
Louis Navellier’s proprietary Portfolio Grader[18] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[19].
Source URL: https://investorplace.com/2013/03/8-biotechnology-stocks-to-sell-now-dsco-achn-ghdx/
Copyright ©2024 InvestorPlace unless otherwise noted.